Does Ozempic Get Covered by Medicare for Weight Loss? What Beneficiaries Need to Know in 2026

Medicare Part D does not cover Ozempic for weight loss, and that rule hasn't changed in 2026. But the landscape around semaglutide weight loss coverage is shifting fast, and knowing exactly what's covered, what isn't, and what's coming next could save you hundreds of dollars a month. This guide breaks it all down.

Why Medicare Won't Cover Ozempic for Weight Loss (Yet)

The rule here is simple, if frustrating. The 2003 Medicare Modernization Act explicitly excludes drugs used solely for weight loss from Medicare Part D coverage. That exclusion has been in place for over two decades and still applies today.

Ozempic (semaglutide) does have FDA approval, but specifically for treating Type 2 diabetes, not obesity. Medicare Part D may cover it when a doctor prescribes it for diabetes management, and the drug appears on a plan's formulary. The moment the prescription is written for weight loss instead, coverage disappears entirely.

This trips people up constantly. They hear that their neighbor's Ozempic is covered and assume theirs will be too. The difference is almost always the diagnosis on the prescription, not the drug itself.

The New Medicare GLP-1 Bridge Program Starting July 1, 2026

Something genuinely new is happening. A temporary Medicare GLP-1 Bridge Program begins on July 1, 2026, and it represents the first time Medicare has offered any coverage for GLP-1 drugs prescribed specifically for weight loss. Millions of Americans could be eligible, according to UCHealth.

Crucially, Ozempic is not on the covered drug list. The program covers Wegovy (as an injection or tablet), Zepbound KwikPen, and Foundayo (tablet form). If you were hoping this program would finally cover your Ozempic prescription for weight loss, it won't.

Who qualifies?

Eligibility requires all of the following:

• Age 18 or older with active Medicare Part D coverage
• A BMI of 35 or higher, OR a BMI of 30 or higher combined with a qualifying condition such as heart failure, uncontrolled hypertension, or chronic kidney disease

What does it cost?

Eligible beneficiaries pay a $50 monthly copayment for a month's supply of a covered medication. The program runs through December 31, 2027. Beyond that, CMS is actively exploring broader models like the BALANCE Model for more comprehensive anti-obesity medication coverage. If you qualify and want to explore Wegovy as an alternative, it's worth confirming your eligibility before the program opens.

What Ozempic Actually Costs Without Medicare Coverage

If Medicare won't cover your Ozempic for weight loss, you're paying out-of-pocket. The numbers aren't small. As of early 2026, injectable Ozempic runs between $199 and $499 per month at retail, depending on the dose. New patients may find introductory pricing at the lower end of that range for the first couple of months.

The oral option, Rybelsus (the semaglutide pill approved for Type 2 diabetes), costs between $149 and $299 monthly for uninsured or self-pay patients. That's still a significant monthly expense for most people on a fixed income.

Manufacturer savings programs exist, but they typically don't apply to Medicare beneficiaries. Federal rules bar most people with Medicare from using these commercial discount cards, which means the out-of-pocket cost you see advertised may not be the cost you actually pay. Some patients order through a licensed Canadian pharmacy as a way to reduce costs, since prices across the border can be substantially lower. You can also check available medication coupons to see if any savings apply to your situation.

When Medicare Does Cover GLP-1s: Beyond Weight Loss

There are situations where Medicare does cover semaglutide or other GLP-1 drugs. Knowing them could change your conversation with your doctor. Wegovy has standard Medicare Part D coverage when prescribed to reduce the risk of major cardiovascular events in adults with established heart disease who are also overweight or obese. That's a specific FDA-approved use, and it's a real coverage pathway for patients who fit that profile.

Medicare Part B covers intensive behavioral therapy for obesity when a patient has a BMI of 30 or higher and receives counseling from a primary care practitioner in a primary care setting. Deductibles and coinsurance are waived for this service, making it genuinely free for qualifying beneficiaries.

Other weight management options covered by Medicare include medical nutrition therapy and bariatric surgery, depending on individual circumstances and plan details. These aren't substitutes for medication, but they're real tools worth knowing about. You can browse medication and drug categories to get a clearer picture of what's available across treatment types.

What's Next: Will Medicare Expand Coverage to Ozempic?

The Bridge Program is a signal, not a solution. For the first time, Medicare is paying for GLP-1 drugs prescribed for weight loss, even if only for specific medications and a limited window. That's a meaningful shift from the blanket exclusion that's been in place since 2003.

CMS is reportedly exploring longer-term models, including something called the BALANCE Model, which could eventually provide more comprehensive coverage for anti-obesity medications. The program runs through December 31, 2027. Beyond that, CMS is actively exploring broader models like the BALANCE Model for more comprehensive anti-obesity medication coverage.

Gross Medicare Part D spending on GLP-1s in 2024 totaled $27.5 billion before rebates, with more than half of that going to semaglutide products, according to KFF. That number makes it hard to ignore the policy question. Whether the federal exclusion of weight loss drugs from Part D changes before or after the Bridge Program ends is uncertain, but the direction of travel seems clear. It remains to be seen if this changes before or after the Bridge Program ends.

In 2026, Medicare Part D plans also cap yearly out-of-pocket costs for covered prescription drugs at $2,100, per Wellcare. That cap matters if you do eventually gain access to covered GLP-1 medications.

Key Takeaways for Medicare Beneficiaries

The bottom line on Ozempic and Medicare in 2026: standard Part D doesn't cover it for weight loss, and that's still federal law. The new GLP-1 Bridge Program changes things for some people, but only for Wegovy, Zepbound KwikPen, and Foundayo, not Ozempic. If you qualify for the Bridge Program (BMI of 35 or higher, or 30 or higher with a qualifying condition), a $50 monthly copayment gets you access to one of those covered alternatives starting July 1, 2026.

For everyone else, the path forward involves reviewing your specific Part D formulary, talking to your doctor about whether a cardiovascular risk indication applies to your situation, and exploring whether a Canadian pharmacy or other cost-reduction strategy makes sense. Staying current on policy changes matters here. The Polar Bear Meds articles section covers updates on GLP-1 coverage and pricing as they develop. And if you're ready to explore your prescription options, you can upload your prescription to get started.